| +0.01 / +0.38%|
The 5 analysts offering 12-month price forecasts for CTi Biopharma Corp have a median target of 4.99, with a high estimate of 6.00 and a low estimate of 4.00. The median estimate represents a +91.25% increase from the last price of 2.61.
The current consensus among 5 polled investment analysts is to Buy stock in CTi Biopharma Corp. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.